Primary Site >> Biliary tract Cancer

Gene >> FGFR2

  • 2001
  • 2010
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
Ref: Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines.
PMID: 11282489
 Ref: Significance of keratinocyte growth factor receptor in the proliferation of biliary tract cancer.
PMID: 21036728
 Ref: Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
PMID: 24122810
Ref: Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
PMID: 24550739
Ref: New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
PMID: 24563076
Ref: Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
PMID: 24837095
 Ref: Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.
PMID: 25608663
Ref: Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
PMID: 25678238
Ref: Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
PMID: 25763789
Ref: Genomic spectra of biliary tract cancer.
PMID: 26258846
 Ref: Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
PMID: 26405193
Ref: Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets.
PMID: 26500333
Ref: The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
PMID: 27102149
Ref: Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
PMID: 27216979
Ref: Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma.
PMID: 27259014
Ref: Biliary cancer: Utility of next-generation sequencing for clinical management.
PMID: 27622582
Ref: Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.
PMID: 27627808
Ref: The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?
PMID: 27747092
Ref: Molecular profiling of biliary tract cancer: a target rich disease.
PMID: 27747093
Ref: Systemic therapy for biliary cancers.
PMID: 27829278
 Ref: Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
PMID: 28034880
Ref: Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
PMID: 28043904
Ref: Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma.
PMID: 28264865
Ref: The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.
PMID: 28567120
Ref: Current biologics for treatment of biliary tract cancers.
PMID: 28736630
Ref: A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.
PMID: 28972963
 Ref: Targeting cholangiocarcinoma.
PMID: 28844952
Ref: Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
PMID: 29182496
Ref: Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
PMID: 29460642
Ref: Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population.
PMID: 29514108
Ref: Molecular genomic landscapes of hepatobiliary cancer.
PMID: 29573058
Ref: Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
PMID: 29848569
Ref: New developments in systemic therapy for advanced biliary tract cancer.
PMID: 29893894
Ref: HSP90 inhibition drives degradation of FGFR2 fusion proteins: implications for treatment of cholangiocarcinoma.
PMID: 30067876
Ref: Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type.
PMID: 30158952
Ref: Sprouty2 suppresses progression and correlates to favourable prognosis of intrahepatic cholangiocarcinoma via antagonizing FGFR2 signalling.
PMID: 30160357